Shots: Verastem to receive $5M up front, $42M as development & commercial milestones and royalties on sales of Copiktra in the licensed territories. Sanofi to get exclusive rights to develop […]readmore
Tags : Verastem Oncology
Shots: The P-III DUO study involves assessing of Copiktra (Duvelisib) vs ofatumumab in 319 patients with r/r CLL (n=312)/SLL (n=7) after at least two prior therapies in ratio 1:1 The […]readmore
Shots: Verastem will receive an upfront of $15M with up to $30M for development milestones, additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib) CSPC to get […]readmore
Shots: The approval is based on DUO (NCT02004522) & DYNAMO (NCT01882803) study results assessing Copiktra (25msg bid) vs ofatumumab or rituximab and to either CT or radioimmunotherapy in 319 adults […]readmore